291 related articles for article (PubMed ID: 38286339)
1. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
[TBL] [Abstract][Full Text] [Related]
2. Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults.
Song R; Li Z; Zhang Y; Tan J; Chen Z
Liver Int; 2024 Apr; 44(4):1051-1060. PubMed ID: 38293788
[TBL] [Abstract][Full Text] [Related]
3. Exploring the landscape of steatotic liver disease in the general US population.
Ciardullo S; Carbone M; Invernizzi P; Perseghin G
Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
[TBL] [Abstract][Full Text] [Related]
4. A prospective study on the prevalence of MASLD in people with type-2 diabetes in the community. Cost effectiveness of screening strategies.
Forlano R; Stanic T; Jayawardana S; Mullish BH; Yee M; Mossialos E; Goldin R; Petta S; Tsochatzis E; Thursz M; Manousou P
Liver Int; 2024 Jan; 44(1):61-71. PubMed ID: 37718933
[TBL] [Abstract][Full Text] [Related]
5. Metabolic dysfunction-associated steatotic liver disease-related hepatic fibrosis increases risk of insulin resistance, type 2 diabetes, and chronic kidney disease.
Zhang W; Song WJ; Chen W; Pan Z; Zhang J; Fan L; Li J
Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):802-810. PubMed ID: 38526946
[TBL] [Abstract][Full Text] [Related]
6. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.
Wang SW; Hsieh TH; Cheng YM; Wang CC; Kao JH
Hepatol Int; 2024 Jun; 18(3):943-951. PubMed ID: 38227142
[TBL] [Abstract][Full Text] [Related]
7. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.
Targher G; Byrne CD; Tilg H
Gut; 2024 Mar; 73(4):691-702. PubMed ID: 38228377
[TBL] [Abstract][Full Text] [Related]
8. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.
Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C
Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290
[TBL] [Abstract][Full Text] [Related]
9. Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease.
Suzuki K; Tamaki N; Kurosaki M; Takahashi Y; Yamazaki Y; Uchihara N; Tanaka Y; Miyamoto H; Yamada M; Keitoku T; Okada R; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Yasui Y; Tsuchiya K; Nakanishi H; Izumi N
Hepatol Res; 2024 Jan; ():. PubMed ID: 38234088
[TBL] [Abstract][Full Text] [Related]
10. Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification?
Ramírez-Mejía MM; Jiménez-Gutiérrez C; Eslam M; George J; Méndez-Sánchez N
Hepatol Int; 2024 Feb; 18(1):168-178. PubMed ID: 38127259
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States.
Gawrieh S; Vilar-Gomez E; Woreta TA; Lake JE; Wilson LA; Price JC; Naggie S; Sterling RK; Heath S; Corey KE; Cachay ER; Ajmera V; Tonascia J; Sulkowski MS; Chalasani N; Loomba R
Aliment Pharmacol Ther; 2024 Mar; 59(5):666-679. PubMed ID: 38158589
[TBL] [Abstract][Full Text] [Related]
12. Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study.
Iwaki M; Fujii H; Hayashi H; Toyoda H; Oeda S; Hyogo H; Kawanaka M; Morishita A; Munekage K; Kawata K; Tsutsumi T; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Kamada Y; Takahashi H; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T
Clin Mol Hepatol; 2024 Apr; 30(2):225-234. PubMed ID: 38263684
[TBL] [Abstract][Full Text] [Related]
13. Steatotic liver disease, MASLD and risk of chronic kidney disease.
Bilson J; Mantovani A; Byrne CD; Targher G
Diabetes Metab; 2024 Jan; 50(1):101506. PubMed ID: 38141808
[TBL] [Abstract][Full Text] [Related]
14. Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD.
Abdelhameed F; Kite C; Lagojda L; Dallaway A; Chatha KK; Chaggar SS; Dalamaga M; Kassi E; Kyrou I; Randeva HS
Curr Obes Rep; 2024 May; ():. PubMed ID: 38809396
[TBL] [Abstract][Full Text] [Related]
15. Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B.
Con D; Tu S; Clayton-Chubb D; Lubel JS; Nicoll AJ; Sawhney R; Bloom S
Dig Dis Sci; 2024 Apr; 69(4):1496-1506. PubMed ID: 38376788
[TBL] [Abstract][Full Text] [Related]
16. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
[TBL] [Abstract][Full Text] [Related]
17. Update in lean metabolic dysfunction-associated steatotic liver disease.
Sato-Espinoza K; Chotiprasidhi P; Huaman MR; Díaz-Ferrer J
World J Hepatol; 2024 Mar; 16(3):452-464. PubMed ID: 38577539
[TBL] [Abstract][Full Text] [Related]
18. Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States.
Golabi P; Paik JM; Kumar A; Al Shabeeb R; Eberly KE; Cusi K; GunduRao N; Younossi ZM
Metabolism; 2023 Sep; 146():155642. PubMed ID: 37380016
[TBL] [Abstract][Full Text] [Related]
19. Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population.
Chew NWS; Pan XH; Chong B; Chandramouli C; Muthiah M; Lam CSP
Diabetes Res Clin Pract; 2024 May; 211():111652. PubMed ID: 38574897
[TBL] [Abstract][Full Text] [Related]
20. Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?
Younossi ZM; Paik JM; Al Shabeeb R; Golabi P; Younossi I; Henry L
Hepatology; 2022 Nov; 76(5):1423-1437. PubMed ID: 35363908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
